Conference Reports for NATAP

Back

ID Week Oct 8-12 2014, Philadelphia     HCV at ID Week-2 2014 David H Shepp, MD Associate Professor of Medicine Hofstra-North Shore LIJ School of Medicine - (10/22/14)   HIV at ID Week 2014 David H Shepp, MD Associate Professor of Medicine Hofstra-North Shore LIJ School of Medicine - (10/22/14)   A Retrospective Study to Evaluate the Effect of Switching Antiretroviral Therapy to a Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate in HIV Infected Patients With Suppressed Viral Load In a Clinical Setting - The Switch to Complera (TSC) Study - (11/03/14)   Peer Recruitment Increases HIV-Positivity Rate CDC Study - Comparative effectiveness of social networks-based strategies versus standard counseling, testing and referral for HIV screening in a state-wide testing program - (10/29/14)   Safety Profile of HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Analysis - (10/29/14)   Evaluation of Drug-Drug Interaction between Daclatasvir and Methadone or Buprenorphine/Naloxone - (10/28/14)   Evaluation of Drug-Drug Interaction Between Asunaprevir and Methadone or Buprenorphine/Naloxone - (10/28/14)   Predictors of Sustained Virological Response in Cancer Survivors with Hepatitis C Virus Infection Receiving Antiviral Therapy. Cancer Patients are a "special population" of HCV-infected & should be prioritized for treatment. - (10/27/14)   One in 5 With HIV in US Never Tested for HCV, Prevalence 21% in Tested - Mark Mascolini - (10/25/14)   Hip Fracture Rate Higher With HIV/HBV Than HIV Alone in Medicaid Analysis - Mark Mascolini - (10/25/14)   Switch to Complera in Clinical Practice Usually Safe and Effective - Mark Mascolini - (10/24/14)   HIV Risk Behavior Increases Between HIV Tests in Half of Wisconsin Group - Mark Mascolini - (10/24/14)   Asking Patients About Sex Only Factor Tied in Syphilis Screening in HIV Group - Mark Mascolini - (10/24/14)   Pregnancy Outcomes and Postdelivery Mortality in Perinatally HIV-Infected Women - Mark Mascolini - (10/24/14)   Preterm Delivery Rate Doubled With HIV in Canada--Boosted PIs Key Factor - Mark Mascolini - (10/24/14)   Only One Third of MSM in Routine HIV Care Tested for Gonorrhea or Chlamydia - Mark Mascolini - (10/24/14)   In-Hospital Antiretroviral Errors Correctly Quickly With Two-Pronged Strategy - Mark Mascolini - (10/24/14)   Current PI, White Race, Lower BMI Linked to Higher Selenium in HIV Group - Mark Mascolini - (10/24/14)   Raltegravir Containing regimen, for Post Exposure Prophylaxis (PEP) well tolerated in Health Care Workers (HCW) - (10/23/14)   Tolerability, adherence and completion of new occupational post-exposure prophylaxis regimen (tenofovir + emtricitabine and raltegravir) - (10/23/14)   Efavirenz & Suicidality....New analysis among Medicaid & Commercial databases finds no association, reflects current EFV use patterns & safer/proper use of EFV....... - (10/23/14)   Longitudinal Trends in HIV Non-Occupational Post-Exposure Prophylaxis (NPEP) at a Boston Community Health Center Between 1997 and 2013 - (10/23/14)   Attitudes and Interest Toward HIV Pre-Exposure Prophylaxis (PrEP) Among Participants Using HIV Non-Occupational Post-Exposure Prophylaxis (NPEP) - (10/23/14)   Veterans Aging Cohort Study (VACS) Index, Functional Status, and Other Patient Reported Outcomes in Older HIV-positive (HIV+) Adults in SF.....Poor Outcomes in HIV+ Aging age 53-61 - (10/23/14)   HCV at IDSA - Bone Disease Greater in HIV+ HCV or HBV Coinfected / Barriers to Care / Hi Prevalence 7% at STD Clinic in Baltimore / 20% of HIV+ Never Tested for HCV / New HCV Therapies: Ledipasvir/Sofosbuvir & Abbvie 3D Data Summaries - (10/17/14)   Characterization of Patients with Viral Hepatitis at an Urban Hospital in Washington, DC 2009-2013 - (10/17/14)   HCV at ID Week 2014 Written by David H Shepp, MD Associate Professor of Medicine Hofstra-North Shore LIJ School of Medicine - (10/17/14)   Three Quarters of NPEP Users Show Interest in Trying PrEP - Mark Mascolini - (10/16/14)   High Rate of NPEP Completion, Good Safety, With Raltegravir Plus TDF/FTC - Mark Mascolini - (10/16/14)   Safety, Tolerability, and Antiretroviral Activity of Raltegravir in HIV-1 Infected Russian Children and Adolescents - a 24 Week Study - (10/16/14)   Commercial and Medicaid Claims Databases Show No Evidence of Higher Suicidality With Efavirenz - Mark Mascolini - (10/15/14)   Increased Risk of Hip Fracture Associated with Dually-Treated HIV/Hepatitis B Virus Coinfection - (10/15/14)   Factors associated with the selection of initial antiretroviral therapy: Real-world channeling - (10/15/14)   A 28-Day High-Dose Safety and Pharmacokinetics Study of Raltegravir in Healthy Subjects - (10/15/14)   Using Real World Data to Assess the Risk of Suicidality among Patients Initiating an Efavirenz versus an Efavirenz-Free Antiretroviral Regimen - (10/15/14)   ABT-450/R/OMBITASVIR AND DASABUVIR WITH RIBAVIRIN ACHIEVES HIGH SUSTAINED VIROLOGIC RESPONSE RATES REGARDLESS OF BASELINE CHARACTERISTICS: POOLED ANALYSES OF THE SAPPHIRE-I AND SAPPHIRE-II STUDIES - (10/15/14)   Ledipasvir/Sofosbuvir is Safe and Effective as a Single-Tablet-Regimen for Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus, Including those with Compensated Cirrhosis - (10/15/14)   IDSA: Safety of ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Patients, by Baseline Demographics - (10/15/14)   HCV Treatment 2014 and Beyond - New Era of Hepatitis C Management - (10/15/14)   Hepatitis C Care among HIV Infected Patients in a Community Based Clinic (Ryan White Clinic/Baltimore) - (10/15/14)   Sexually Transmitted Diseases Clinic Based Hepatitis C Testing and Linkage to care - Hi prevalence 7%, low attendance at offsite HCV specialist appointments - (10/15/14)   Prevalence of and Factors Associated with Hepatitis C Virus Testing and Infection Among HIV-infected Adults Receiving Medical Care in the United States .... 20% Never Tested/21% HCV+/MSM Lo % Tested/Homelessness associated with HCV+ - (10/15/14)   Optimization of the HCV Testing and Care Continuum in an Urban Federally Qualified Health Center in Denver - (10/15/14)   Safety, Tolerability, and Antiretroviral Activity of Raltegravir in HIV-1 Infected Russian Children and Adolescents - a 24 Week Study - (10/14/14)   Structural Bone Deficits in HIV/HCV, HCV-Monoinfected, and HIV-Monoinfected Women - (10/14/14)   Non-Genotype 1 HCV Predicts Sustained Virologic Response in Cancer Survivors - written by Mark Mascolini - (10/14/14)   Erectile Dysfunction Drug Use Tied to Sexual Risk and STIs in HIV+ US Men - written by Mark Mascolini - (10/14/14)   Low Trabecular BMD, High TNF-Alpha in Women With HIV/HCV vs Only HIV or HCV - written by Mark Mascolini - (10/14/14)   Almost 80% of Visits to Bronx Center Rank as Missed Chances for HIV Diagnosis - written by Mark Mascolini - (10/14/14)   ROC Curves Pinpoint ART Failure Threshold at 95 Copies at Week 24 - written by Mark Mascolini - (10/14/14)   HCV Treatment Cascade: Is Eradication Possible? - (10/10/14)   Evaluation of Drug-Drug Interaction between Daclatasvir and Methadone or Buprenorphine/Naloxone - (10/10/14)   HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis - (10/10/14)   STaR: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF has similar efficacy and is well-tolerated compared to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve females at Week 96 - (10/10/14)   Simplification to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF from Ritonavir-Boosted Protease Inhibitor Plus Emtricitabine/Tenofovir DF Maintains HIV Suppression and Improves Fasting Triglycerides at Week 48 - (10/10/14)   HIV-1 Attachment Inhibitor Prodrug BMS-663068 in Antiretroviral-Experienced Subjects: Week 24 Subgroup Analysis - (10/10/14)   HIV Care Cascade Differs by Gender and Age in Large US Healthcare System - written by Mark Mascolini - (10/10/14)   More Positive HIV Tests Via Social Networks Than Standard Approach - written by Mark Mascolini - (10/10/14)   Risk Score and Race Predict Missed HIV Appointments in US Group - written by Mark Mascolini - (10/10/14)   Gender, Depression, Heart and Liver Disease Affect First-Line ART Choice in US - written by Mark Mascolini - (10/10/14)   Acute Retroviral Syndrome Tied to Higher HIV RNA and DNA in Blood, Colon, CSF - written by Mark Mascolini - (10/10/14)   Delayed HIV Rebound More Frequent After Early Treatment and With NNRTIs - written by Mark Mascolini - (10/10/14)